Viatris

Viatris Inc. is an American-based global healthcare company formed through the merger of Mylan and Upjohn on November 16, 2020.[3]

Viatris Inc.
TypePublic
ISINUS92556V1061
IndustryPharmaceuticals
Predecessors
FoundedNovember 16, 2020 (2020-11-16)
Headquarters,
United States of America
Area served
Worldwide
Key people
Robert J. Coury (Executive Chairman)
Michael Goettler (CEO)
ProductsBranded and generic pharmaceuticals and active pharmaceutical ingredients
Revenue$11 Billion (2019)[1]
Number of employees
45,000[2]
Websitewww.viatris.com

The name comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the company set.[4][5]

At the time of the combination, Michael Goettler became CEO of the new company.[3][6][7][8] Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS.[3]

The company produces and sells different types of medicines: brands (like Viagra, Xanax, Lipitor),[9][10] generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients.[11] They belong to a wide range of therapeutic areas, such as cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology.[12]

History

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

Viatris Acquisitions

References

  1. https://www.macrotrends.net/stocks/charts/VTRS/viatris/revenue
  2. https://www.bizjournals.com/pittsburgh/news/2020/12/11/viatris-to-lay-off-up-to-20-of-global-workforce.html
  3. Gough, Paul J. (16 November 2020). "After nearly 60 years, Mylan makes way for Viatris". Pittsburgh Business Times. Retrieved 16 November 2020.
  4. "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette. Retrieved 2021-01-04.
  5. "Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?". FiercePharma. Retrieved 2021-01-04.
  6. Mamula, Kris B. (29 July 2019). "Mylan merger with Pfizer's Upjohn unit to form new company with $20 billion in revenues". Pittsburgh Post-Gazette. Retrieved 16 November 2020.
  7. Sabatini, Patricia (12 November 2019). "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette. Retrieved 16 November 2020.
  8. "Our Leaders". www.viatris.com. Retrieved 2021-01-04.
  9. "Products". www.viatris.com. Retrieved 2021-01-04.
  10. "Mylan merger with Pfizer's Upjohn unit to form new company with $20 billion in revenues". Pittsburgh Post-Gazette. Retrieved 2021-01-04.
  11. "Our Story". www.viatris.com. Retrieved 2021-01-04.
  12. "Therapeutic Areas". www.viatris.com. Retrieved 2021-01-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.